Will Outcomes-Based Payments Hit COPD Drugs?
November 29, 2018
In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?
Formulary
Will Drug Price Hikes Impact Drug Spending?
November 28, 2018
Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.
Formulary Drug Exclusions on the Rise: What Health Execs Should Know
August 2, 2018
A 51-year-old female patient has been taking Forteo (teriparatide) for osteoporosis for the past year. Her insurance company notifies her that the drug is no longer on its formulary.
How Payers are Responding to Growing Orphan Drug Costs
April 26, 2018
Payers are stepping up efforts to manage the cost and utilization of orphan drug treatments.
‘Encouraging’ COPD drug pipeline could ease symptoms, address root causes
November 7, 2017
Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.
Survey: How payers use nonpayer generated data to make formulary decisions
October 19, 2017
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Three Orphan Drug Program problems and how the FDA plans to fix them
October 11, 2017
Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.
Expedited FDA approval plays dominant role in drug approvals
March 30, 2017
Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Top considerations when determining whether to approve expensive drugs
March 30, 2017
Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Opinion: More industry-stakeholders play blame game for high drug costs
March 23, 2017
Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
